1. Home
  2. SENS vs GALT Comparison

SENS vs GALT Comparison

Compare SENS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

N/A

Current Price

$9.66

Market Cap

397.1M

Sector

Industrials

ML Signal

N/A

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

397.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SENS
GALT
Founded
1996
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.1M
397.3M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
SENS
GALT
Price
$9.66
$3.45
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $13.67
N/A
AVG Volume (30 Days)
★ 581.7K
191.4K
Earning Date
11-09-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 36.84
EPS
N/A
★ N/A
Revenue
★ $16,389,000.00
N/A
Revenue This Year
$82.21
N/A
Revenue Next Year
$55.63
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.85
N/A
52 Week Low
$4.79
$2.03
52 Week High
$10.64
$7.13

Technical Indicators

Market Signals
Indicator
SENS
GALT
Relative Strength Index (RSI) 57.37 49.26
Support Level $5.07 $2.71
Resistance Level $10.13 $4.10
Average True Range (ATR) 0.72 0.28
MACD 0.09 0.00
Stochastic Oscillator 93.05 68.75

Price Performance

Historical Comparison
SENS
GALT

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: